Company Filing History:
Years Active: 2021-2023
Title: Dirk Scharn: Innovator in Oncology Therapeutics
Introduction
Dirk Scharn is a prominent inventor based in Vienna, Austria. He has made significant contributions to the field of oncology through his innovative research and development of pharmaceutical compounds. With a total of 4 patents to his name, Scharn is recognized for his work in creating effective treatments for oncological diseases.
Latest Patents
One of Scharn's latest patents is focused on substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors. This invention relates to new [1,3]diazino[5,4-d]pyrimidines and their derivatives, which are designed to inhibit HER2 and its mutants. The patent also covers pharmaceutical compositions containing these compounds and their application as medicaments for the treatment and prevention of oncological diseases. Another significant patent involves [1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors. This invention encompasses compounds that serve as inhibitors of CDK8/19, along with their pharmaceutical compositions and use as agents for treating oncological diseases.
Career Highlights
Dirk Scharn is currently employed at Boehringer Ingelheim International GmbH, a leading global pharmaceutical company. His work at Boehringer Ingelheim has allowed him to focus on developing innovative solutions for cancer treatment. Scharn's expertise in medicinal chemistry and drug development has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Throughout his career, Scharn has collaborated with notable colleagues, including Harald Engelhardt and Heribert Arnhof. These collaborations have fostered a productive environment for research and innovation, contributing to the advancement of oncology therapeutics.
Conclusion
Dirk Scharn's contributions to the field of oncology through his patents and work at Boehringer Ingelheim highlight his commitment to improving cancer treatment options. His innovative research continues to pave the way for new therapeutic approaches in the fight against oncological diseases.